Business Wire

Updated Regula Face SDK Blocks 99% of Presentation Attacks Via Electronic Devices

3.4.2024 10:00:00 EEST | Business Wire | Press release

Share

When it comes to verifying identity in remote scenarios, it’s generally through liveness checks that organizations try to ensure they are dealing with a real individual. Fraudsters are perfectly aware of this fact, and therefore seek to bypass verification using various tactics, predominantly presentation or injection attacks. The first type of fraud involves attempts to trick the system by presenting fake biometric traits, such as photos, videos, masks, etc. Injection attacks are done by inserting altered biometric data directly into the process of identity verification (IDV).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403567119/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

A presentation attack scenario blocked by Regula Face SDK (Photo: Business Wire)

To help organizations secure remote IDV processes, Regula offers powerful technologies capable of detecting even the most sophisticated biometric fraud, including presentation and injection attacks. This latest update marks an advancement in Regula’s ability to detect certain types of spoofing attacks.

Enhanced security. Now, Regula Face SDK, a comprehensive solution for biometric verification, has reached a 99% rate in detecting and blocking presentation attacks done from electronic devices. Its anti-spoofing technology ensures that the face detected during the verification process is from an actively present and real person.

Streamlined user experience. Also, the new release of Regula Face SDK brings a new level of usability to biometric verification, thanks to the introduction of Passive Liveness technology. Utilizing neural networks trained on a diverse dataset, this technology verifies the genuine presence of an individual without any active participation from users (unlike Active Liveness) – the solution just requires them to take a selfie.

To obtain proper data for verification, i.e., a high-quality face image, Regula Face SDK uses an advanced image capture module that assesses image quality in real time, reducing the need for retakes. Followed by an instant liveness check, this approach significantly streamlines the overall verification process, making it faster and more user-friendly while maintaining high security standards.

“Remote onboarding is our new reality. More risky for organizations and definitely more preferable for users, it is about finding the perfect balance between security and convenience. The Passive Liveness feature is a delicate solution to this equation. It’s a very accessible single step for the user, improving user experience and elevating conversion rates. But that’s not all: Passive Authentication still ensures a high level of trustworthiness in the IDV process, as it effectively proves the presence and realness of an individual. Plus, for those who need ultimate security during onboarding or user verification, there is still the option of choosing Active Liveness, a more user-involving and robust technology for proving liveness,” says Ihar Kliashchou, Chief Technology Officer at Regula.

For the sake of greater convenience and faster interaction, the updated Regula Face SDK also supports face matching on mobile devices, without transmitting data to a server. Now, even if a smartphone is offline, it is still possible to compare a photo from a document with a selfie when identity verification is done not remotely, but on-site by an employee, for example in a bank when a client wants to open an account or get access to other financial services.

To learn more about the capabilities of the new version of Regula Face SDK, visit the official webpage.

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.

Learn more at www.regulaforensics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kristina – ks@regulaforensics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye